Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001140361-21-037545
Filing Date
2021-11-12
Accepted
2021-11-12 08:31:24
Documents
70
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q brhc10030460_10q.htm   iXBRL 10-Q 1362102
2 EXHIBIT 10.1 brhc10030460_ex10-1.htm EX-10.1 11452
3 EXHIBIT 31.1 brhc10030460_ex31-1.htm EX-31.1 7656
4 EXHIBIT 31.2 brhc10030460_ex31-2.htm EX-31.2 7661
5 EXHIBIT 32.1 brhc10030460_ex32-1.htm EX-32.1 5316
6 EXHIBIT 32.2 brhc10030460_ex32-2.htm EX-32.2 5332
  Complete submission text file 0001140361-21-037545.txt   6736982

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA ocup-20210930.xsd EX-101.SCH 63488
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ocup-20210930_cal.xml EX-101.CAL 40676
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ocup-20210930_def.xml EX-101.DEF 308675
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE ocup-20210930_lab.xml EX-101.LAB 725668
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ocup-20210930_pre.xml EX-101.PRE 445317
12 EXTRACTED XBRL INSTANCE DOCUMENT brhc10030460_10q_htm.xml XML 925075
Mailing Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335
Business Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335 248-681-9815
Ocuphire Pharma, Inc. (Filer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34079 | Film No.: 211399939
SIC: 2834 Pharmaceutical Preparations